Granules India reports 62.5 percent fall in Q1 profit
Revenue from operations fell 3.3% to 9.85 billion rupees.
Hyderabad: Granules India Ltd, the maker of paracetamol and ibuprofen pain relievers, reported a 62.5% fall in first-quarter profit on Wednesday, as a cyber security incident significantly disrupted operations.The generic drug maker’s consolidated net profit tumbled to 478.9 million rupees ($5.8 million) in the April-June quarter, from 1.27 billion rupees a year earlier.Granules faced a...
Hyderabad: Granules India Ltd, the maker of paracetamol and ibuprofen pain relievers, reported a 62.5% fall in first-quarter profit on Wednesday, as a cyber security incident significantly disrupted operations.
Granules faced a cyber security attack in May, which caused major disruptions in its operations, affecting its IT assets. A ransomware group has claimed responsibility, the company said.
“(It) took considerable time to address the regulatory expectations, qualifications, fine-tuning of quality and production systems. This has impacted significantly the revenue and profitability for the quarter,” Granules said.
Revenue from operations fell 3.3% to 9.85 billion rupees.
“Operating expenses were higher, in line with the expected revenue, and hence the gap in sales had a severe impact on PAT,” said Chairman and Managing Director Krishna Prasad Chigurupati.
He said business has been restored to normal.
The fall in profit also comes as generic drug makers grapple with intense price competition in the U.S. and Europe from where they draw a bulk of the revenue.
Granules specialises in manufacturing active pharmaceutical ingredients (API), pharmaceutical formulation intermediates (PFI) and finished dosages (FD).
Granules, which holds a 30% share of the global market for paracetamol, manufactures the drug’s API and also finished dosage, ready for consumption, in European markets.
Revenue from the finished dosage segment, its biggest, fell 2.1% to 5.37 billion rupees, while the API segment, its second-largest, rose 28.1% due to strong paracetamol volumes, the company said.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd